Expression of MOS Gene and Its Correlations with Clinicopathological Features and Prognosis of Patients with Colorectal Cancer
1.Department of TCM Surgery,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China
2.Department of Traditional Chinese Medicine,Peking University Shougang Hospital,Beijing 100144,China
3.Department of Anorectal Surgery,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100007,China
*Corresponding author:PENG Jisheng,Associate chief physician;E-mail:naitao847424021@163.com
PENG Junfu,PENG Jisheng,WANG Rui, et al. Expression of MOS Gene and Its Correlations with Clinicopathological Features and Prognosis of Patients with Colorectal Cancer [J]. Chinese General Practice, 2021, 24(24): 3077-3081. DOI: 10.12114/j.issn.1007-9572.2021.00.434.
彭俊付,彭继升,王锐等. 结直肠癌患者MOS基因表达情况及其与患者临床病理特征和预后的关系研究[J]. 中国全科医学, 2021, 24(24): 3077-3081. DOI: 10.12114/j.issn.1007-9572.2021.00.434.
[1]TESTA U,PELOSI E,CASTELLI G.Colorectal cancer:genetic abnormalities,tumor progression,tumor heterogeneity,clonal evolution and tumor-initiating cells[J].Med Sci(Basel),2018,6(2):31.DOI:10.3390/medsci6020031.
[2]王锡山.中美结直肠癌流行病学特征及防诊治策略的对比分析[J].中华结直肠疾病电子杂志,2017,6(6):447-453.DOI:10.3877/cma.j.issn.2095-3224.2017.06.002.
WANG X S.Comparison analysis of epidemiological characteristics and prevention-treatment strategy of colorectal cancer in China and the United States[J].Chinese Journal of Colorectal Diseases(Electronic Edition),2017,6(6):447-453.DOI:10.3877/cma.j.issn.2095-3224.2017.06.002.
[3]CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[4]MITRUGNO A,SYLMAN J L,NGO A T P,et al.Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation:implications for the oncoprotein c-MYC[J].Am J Cell Physiol,2017,312(2):C176-189.DOI:10.1152/ajpcell.00196.2016.
[5]WINAWER S J,ZAUBER A G,HO M N,et al.Prevention of colorectal cancer by colonoscopic polypectomy.The National Polyp Study Workgroup[J].N Engl J Med,1993,329(27):1977-1981.DOI:10.1056/NEJM199312303292701.
[6]PRASAD C K,MAHADEVAN M,MACNICOL M C,et al.Mos 3' UTR regulatory differences underlie species-specific temporal patterns of Mos mRNA cytoplasmic polyadenylation and translational recruitment during oocyte maturation[J].Mol Reprod Dev,2008,75(8):1258-1268.DOI:10.1002/mrd.20877.
[7]PROPST F,ROSENBERG M P,IYER A,et al.c-mos proto-oncogene RNA transcripts in mouse tissues:structural features,developmental regulation,and localization in specific cell types[J].Mol Cell Biol,1987,7(5):1629-1637.DOI:10.1128/MCB.7.5.1629.
[8]GEBAUER F,RICHTER J D.Synthesis and function of Mos:the control switch of vertebrate oocyte meiosis[J].Bioessays,1997,19(1):23-28.DOI:10.1002/bies.950190106.
[9]CAO S F,LI D,YUAN Q,et al.Spatial and temporal expression of c-mos in mouse testis during postnatal development[J].Asian J Androl,2008,10(2):277-285.DOI:10.1111/j.1745-7262.2008.00324.x.
[10]DE FOY K A,GAYTHER S A,COLLEDGE W H,et al.Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas[J].Br J Cancer,1998,77(10):1642-1644.DOI:10.1038/bjc.1998.269.
[11]OGISO Y,MATSUMOTO M,MORITA T,et al.Expression of c-mos proto-oncogene in undifferentiated teratocarcinoma cells[J].Biochem Biophys Res Commun,1986,140(2):477-484.DOI:10.1016/0006-291x(86)90757-6.
[12]ZACHARATOS P,KOTSINAS A,TSANTOULIS P,et al.Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas[J].Mol Med,2001,7(9):590-597.DOI:10.1007/BF03401865.
[13]GORGOULIS V G,ZACHARATOS P,MARIATOS G,et al.Deregulated expression of c-mos in non-small cell lung carcinomas:relationship with p53 status,genomic instability,and tumor kinetics[J].Cancer Res,2001,61(2):538-549.
[14]XERRI L,CHARPIN C,HASSOUN J,et al.Mos oncogene expression in human ovarian tumors[J].Anticancer Res,1991,11(4):1629-1634.
[15]PARKAR M H,SEID J M,STRINGER B M,et al.Abnormal expression of the MOS proto-oncogene in human thyroid medullary carcinoma[J].Cancer Lett,1988,43(3):185-189.DOI:10.1016/0304-3835(88)90169-3.
[16]OGUNWOBI O O,MAHMOOD F,AKINGBOYE A.Biomarkers in colorectal cancer:current research and future prospects[J].Int J Mol Sci,2020,21(15):5311.DOI:10.3390/ijms21155311.
[17]SANCHEZ-IBARRA H E,JIANG X,GALLEGOS-GONZALEZ E Y,et al.KRAS,NRAS,and BRAF mutation prevalence,clinicopathological association,and their application in a predictive model in Mexican patients with metastatic colorectal cancer:a retrospective cohort study[J].PLoS One,2020,15(7):e0235490.DOI:10.1371/journal.pone.0235490.
[18]MORO A,MEHTA R,TSILIMIGRAS D I,et al.Prognostic factors differ according to KRAS mutational status:a classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis[J].Surgery,2020,168(3):497-503.DOI:10.1016/j.surg.2020.05.019.
[19]SUENAGA M,SCHIRRIPA M,CAO S,et al.Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab:analysis of the TRIBE Trial[J].Cancers(Basel),2020,12(7):1742.DOI:10.3390/cancers12071742.
[20]LINDNER A U,CARBERRY S,MONSEFI N,et al.Systems analysis of protein signatures predicting cetuximab responses in KRAS,NRAS,BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer[J].Int J Cancer,2020,147(10):2891-2901.DOI:10.1002/ijc.33226.
[21]LI Z N,ZHAO L,YU L F,et al.BRAF and KRAS mutations in metastatic colorectal cancer:future perspectives for personalized therapy[J].Gastroenterol Rep(Oxf),2020,8(3):192-205.DOI:10.1093/gastro/goaa022.
[22]SFAKIANAKI M,PAPADAKI C,TZARDI M,et al.PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer[J].Cancers(Basel),2020,12(8):2058.DOI:10.3390/cancers12082058.
[23]PERUNOVIC B,ATHANASIOU A,QUILTY R D,et al.Expression of mos in astrocytic tumors and its potential role in neoplastic progression[J].Hum Pathol,2002,33(7):703-707.DOI:10.1053/hupa.2002.125377.
[24]LI C C,CHEN E,O'CONNELL C D,et al.Detection of c-mos proto-oncogene expression in human cells[J].Oncogene,1993,8(6):1685-1691.DOI:10.1038/ng0693-206.
[25]SINGH B,ARLINGHAUS R B.Vimentin phosphorylation by p37mos protein kinase in vitro and generation of a 50-kDa cleavage product in v-mos-transformed cells[J].Virology,1989,173(1):144-156.DOI:10.1016/0042-6822(89)90230-4.
[26]ZHOU R P,OSKARSSON M,PAULES R S,et al.Ability of the c-mos product to associate with and phosphorylate tubulin[J].Science,1991,251(4994):671-675.DOI:10.1126/science.1825142.
[27]LIU H,VUYYURU V B,PHAM C D,et al.Evidence of an interaction between Mos and Hsp70:a role of the Mos residue serine 3 in mediating Hsp70 association[J].Oncogene,1999,18(23):3461-3470.DOI:10.1038/sj.onc.1202699.
[28]SINGH B,ARLINGHAUS R B.Mos and the cell cycle[J].Prog Cell Cycle Res,1997,3:251-259.DOI:10.1007/978-1-4615-5371-7_20.
[29]FUKASAWA K,VANDE WOUDE G F.Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability[J].Mol Cell Biol,1997,17(1):506-518.DOI:10.1128/MCB.17.1.506.
[30]ATHANASIOU A,GORGOULIS V G,ZACHARATOS P,et al.c-mos immunoreactivity is an indicator of good prognosis in lung cancer[J].Histopathology,2010,37(1):45-54.DOI:10.1046/j.1365-2559.2000.00898.x.